{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:16:42Z","timestamp":1788538602537,"version":"build-2803163510"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Opioids remain central to management of acute and chronic pain in sickle cell disease (SCD). Opioid dispensing declined over the 2010s amid opioid stewardship efforts, but patterns since 2020 are less clear. Analyses aggregating opioids into morphine milligram equivalents (MME) may obscure agent-specific patterns.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize opioid dispensing volume and per-recipient frequency, duration, and dose among individuals with SCD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort study of commercially insured and Medicaid-enrolled patients with SCD using the Merative MarketScan databases across 3 periods from January 2011 to February 2016, March 2016 to December 2020, and January 2021 to December 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Calendar time across 3 prespecified periods: January 2011 to February 2016, March 2016 to December 2020, and January 2021 to December 2023.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Changes in opioid dispensing were examined across 3 periods (January 2011 to February 2016, March 2016 to December 2020, and January 2021 to December 2023). Segmented regression models estimated monthly percentage changes (MPCs) in 4 outcomes: (1) total dispensed prescriptions per 100 enrollees; and, among enrollees receiving opioids, (2) mean prescriptions per person, (3) mean days supplied, and (4) mean daily MMEs. Analyses included 6 opioids (hydromorphone, hydrocodone, morphine, tramadol, oxycodone, methadone) stratified by insurance type (commercial vs Medicaid).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Across 48\u202f760 individuals with SCD contributing person-time, 24\u202f692 (50.6%) were Medicaid beneficiaries, 20\u202f969 (43.0%) were aged 19 to 40 years, and 29\u202f380 (60.3%) were female. From January 2021 through December 2023, total dispensing increased for all 6 agents among Medicaid beneficiaries, with the largest monthly increases for methadone (MPC, 1.76%; 95% CI, 1.24% to 2.29%) and hydromorphone (MPC, 1.43%; 95% CI, 1.00% to 1.86%). Among commercial enrollees, total dispensing increased for oxycodone (MPC, 0.84%; 95% CI, 0.60% to 1.07%) and morphine (MPC, 0.87%; 95% CI, 0.42% to 1.33%), was stable for hydrocodone, hydromorphone, and methadone, and declined for tramadol (MPC, \u22120.79%; 95% CI, \u22121.16% to \u22120.42%). Dispensed prescriptions increased only for oxycodone among commercially insured individuals (MPC, 0.14%; 95% CI, 0.08% to 0.20%) and tramadol among those with Medicaid (MPC, 0.96%; 95% CI, 0.56% to 1.36%). Mean days supplied and mean daily MMEs did not significantly increase for any opioid-insurance combination.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among individuals with SCD, total opioid dispensing increased or stabilized during 2021 to 2023 after prior declines, most prominently among Medicaid beneficiaries, without broad increases in per-recipient frequency, duration, or dose. These patterns are consistent with broader distribution of opioid dispensing rather than treatment intensification among recipients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.32141","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:37:13Z","timestamp":1788536233000},"page":"e2632141","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease"],"prefix":"10.1001","volume":"9","author":[{"given":"Kevin Y.","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri"},{"name":"Center for Advancing Health Services, Policy & Economics Research, Washington University, St Louis, Missouri"},{"name":"Washington University School of Public Health, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Attell","sequence":"additional","affiliation":[{"name":"Georgia Health Policy Center, Georgia State University, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna L.","family":"Buss","sequence":"additional","affiliation":[{"name":"Center for Advancing Health Services, Policy & Economics Research, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tashalee R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California Los Angeles David Geffen School of Medicine, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Jonassaint","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Saint Louis University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"King","sequence":"additional","affiliation":[{"name":"Washington University School of Public Health, St Louis, Missouri"},{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, St Louis Children\u2019s Hospital, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Jordan","family":"Nguemeni Tiako","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"zoi260884r1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1182\/hematology.2020000143","article-title":"Optimizing the management of chronic pain in sickle cell disease.","volume":"2020","author":"Osunkwo","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"zoi260884r2","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: a critical reappraisal.","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"issue":"8","key":"zoi260884r3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.socscimed.2010.07.030","article-title":"The public health critical race methodology: praxis for antiracism research.","volume":"71","author":"Ford","year":"2010","journal-title":"Soc Sci Med"},{"issue":"2-3","key":"zoi260884r4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/CH-189002","article-title":"Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management.","volume":"68","author":"Ballas","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"zoi260884r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134534","article-title":"Opioid treatment for acute and chronic pain in patients with sickle cell disease.","volume":"714","author":"Carroll","year":"2020","journal-title":"Neurosci Lett"},{"issue":"15","key":"zoi260884r6","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016.","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"zoi260884r7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/epirev\/mxaa002","article-title":"Prescription drug monitoring programs and prescription opioid-related outcomes in the United States.","volume":"42","author":"Puac-Polanco","year":"2020","journal-title":"Epidemiol Rev"},{"issue":"5","key":"zoi260884r8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7326\/M21-4363","article-title":"Effects of state opioid prescribing laws on use of opioid and other pain treatments among commercially insured U.S. adults.","volume":"175","author":"McGinty","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi260884r9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the centers for disease control and prevention\u2019s 2016 opioid guideline.","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi260884r10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pds.4291","article-title":"Characterization of opioid use in sickle cell disease.","volume":"27","author":"Han","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi260884r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101214","article-title":"Ten-year trends in opioid prescribing and vaso-occlusive crises in sickle cell disease: a population-based national cohort study (2011-2022).","volume":"50","author":"Xu","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"5","key":"zoi260884r12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamainternmed.2023.8538","article-title":"Opioid prescribing and outcomes in patients with sickle cell disease post-2016 CDC guideline.","volume":"184","author":"Kang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"zoi260884r13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.genhosppsych.2024.09.013","article-title":"Opioid-related emergency admissions in people with opioid dependence\/use disorder with and without sickle cell disease: an analysis of multi-state insurance claims.","volume":"91","author":"Liu","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"key":"zoi260884r14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.genhosppsych.2023.12.001","article-title":"The misuse of malingering diagnoses in individuals with sickle cell disease.","volume":"87","author":"Brown","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"zoi260884r15","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association.","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"issue":"12","key":"zoi260884r16","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"zoi260884r17","doi-asserted-by":"publisher","first-page":"e1971","DOI":"10.1089\/tmj.2023.0422","article-title":"Assessing patterns of telehealth use among people with sickle cell disease enrolled in medicaid during the start of the COVID-19 pandemic.","volume":"30","author":"Reeves","year":"2024","journal-title":"Telemed J E Health"},{"issue":"1","key":"zoi260884r18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12873-024-01043-5","article-title":"Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease.","volume":"24","author":"Attell","year":"2024","journal-title":"BMC Emerg Med"},{"issue":"8","key":"zoi260884r19","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1097\/j.pain.0000000000003529","article-title":"Standardizing research methods for opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator.","volume":"166","author":"Adams","year":"2025","journal-title":"Pain"},{"issue":"12","key":"zoi260884r20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28703","article-title":"Administrative data identify sickle cell disease: a critical review of approaches in U.S. health services research.","volume":"67","author":"Grosse","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"zoi260884r21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/1475-6773.13257","article-title":"Performance of ICD-10-CM diagnosis codes for identifying children with sickle cell anemia.","volume":"55","author":"Reeves","year":"2020","journal-title":"Health Serv Res"},{"issue":"13","key":"zoi260884r22","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1182\/bloodadvances.2022008965","article-title":"The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease.","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"zoi260884r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.44546","article-title":"Use of disease-modifying treatments in patients with sickle cell disease.","volume":"6","author":"Newman","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260884r24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jamapediatrics.2023.6500","article-title":"Opioid use after first opioid prescription in children with sickle cell disease.","volume":"178","author":"Snyder","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"6","key":"zoi260884r25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis.","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"4","key":"zoi260884r26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"zoi260884r27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jphs.12215","article-title":"Opioids in Georgia medicaid: gender and insurance disparities in utilization and potential inappropriate prescribing practices.","volume":"9","author":"Jayawardhana","year":"2018","journal-title":"J Pharm Health Serv Res"},{"issue":"3","key":"zoi260884r28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jama.2021.10161","article-title":"Prescription drug monitoring program mandates and opioids dispensed following emergency department encounters for patients with sickle cell disease or cancer with bone metastasis.","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"zoi260884r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4410","article-title":"Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study.","volume":"2","author":"Sinha","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260884r30","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1182\/bloodadvances.2024013594","article-title":"Changes in acute care use among people with sickle cell disease after adoption of a prescription drug monitoring program.","volume":"9","author":"McGee","year":"2025","journal-title":"Blood Adv"},{"key":"zoi260884r31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3389\/fpsyt.2019.00704","article-title":"A systematic review of laboratory evidence for the abuse potential of tramadol in humans.","volume":"10","author":"Dunn","year":"2019","journal-title":"Front Psychiatry"},{"key":"zoi260884r32","doi-asserted-by":"publisher","DOI":"10.2196\/57290","article-title":"Prevalence, mortality, and access to care for chronic kidney disease in medicaid-enrolled adults with sickle cell disease in California: retrospective cohort study.","volume":"10","author":"Valle","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"zoi260884r33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-pharmtox-022124-022000","article-title":"Treating sickle cell disease: gene therapy approaches.","volume":"65","author":"Cavazzana","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853786\/xu_2026_oi_260884_1788194884.63648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:37:14Z","timestamp":1788536234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.32141","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}